Plaintiff

UFCW Local 1500 Welfare Fund

5 cases as plaintiff.

Cases
5
Active
1
4 closed
Filed
2020
Top venue
N D Ill
2 cases

Company profile

UFCW Local 1500 Welfare Fund is a multi-employer, Taft-Hartley health and welfare benefit trust headquartered at 425 Merrick Avenue, Westbury, New York. It is a VEBA — a tax-exempt voluntary employees' beneficiary association under IRC §501(c)(9) (EIN 23-7176373) — sponsored and administered by a Board of Trustees composed of union and employer representatives. It is not a company with equity, a ticker, or a parent; it is a nonprofit benefit fund. IRS Form 990 data reported by tax-exempt-organization trackers lists assets above $50 million. Employee counts and revenue figures are not applicable to a benefit trust.

Operations. The Fund provides health and welfare benefits to participants covered by UFCW Local 1500, the New York retail-food union chartered in 1937 (roughly 16,000–18,000 members in the New York City metropolitan area). Plans include Full-Time, Special Part-Time, and Part-Time ACA group benefit programs covering self-funded hospital, medical, prescription drug, dental, and vision benefits, plus Anthem-insured group term life, AD&D, and New York statutory disability coverage. Administration is handled with Associated Administrators, LLC. Its operations are benefit administration and drug/medical cost management — it makes no products and owns no patents.

Litigation posture. The Fund is neither an NPE nor a patent owner. All five tracked cases list it as plaintiff and none as defendant. Every tracked matter was filed on 30 June 2020 against Jazz Pharmaceuticals Ireland Ltd. (and affiliates), pleaded as federal and state antitrust claims under the Sherman Act rather than patent infringement. It is a purchaser-side, end-payor class plaintiff challenging allegedly anticompetitive conduct — not an entity asserting patents.

Notable cases. The tracked suits (N.D. Ill. and E.D.N.Y.) were consolidated into In re Xyrem (Sodium Oxybate) Antitrust Litigation, MDL No. 2966, in the Northern District of California, where the Fund appears with other health plans and funds. The litigation concerns Jazz's sodium oxybate (Xyrem) patents — including U.S. 7,668,730 and 7,765,106 — and patent-settlement/REMS conduct delaying generic entry. Jazz disclosed an April 2025 settlement with the indirect-purchaser class; the Fund's status in the remaining proceedings is not separately verifiable from public sources.

Keep this research.

Save to your free workspace, then choose whether to receive updates.

UFCW Local 1500 Welfare Fund v. Jazz Pharmaceuticals Ireland Ltd.

transferred to MDL
Docket:
1:20-cv-03852
Court:
N.D. Ill.
Filed:
2020-06-30
Terminated:
2020-07-22
Patents:7765107

Xyrem antitrust action filed in N.D. Ill. and terminated July 22, 2020 when transferred to the Xyrem MDL. US 7,765,107 is listed among the patents at issue in the narrative.